{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:24:49Z","timestamp":1747207489993,"version":"3.40.5"},"reference-count":35,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2020,6,17]]},"abstract":"<jats:sec>\n<jats:title>Background :<\/jats:title>\n<jats:p>Endocannabinoids (ECs) modulate both excitatory and inhibitory components\nin the CNS. There is a growing body of evidence that shows ECs influence both hypothalamic orexinergic\nand histaminergic neurons involved in narcolepsy physiopathology. Therefore, ECs may influence\nsleep and sleep-wake cycle.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective :<\/jats:title>\n<jats:p>To evaluate EC levels in the CSF of untreated narcoleptic patients to test whether ECs are\ndysregulated in Narcolepsy Type 1 (NT1) and Type 2 (NT2).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods :<\/jats:title>\n<jats:p>We compared CSF Anandamide (AEA), 2-Arachidonoylglycerol (2-AG) and orexin in narcoleptic\ndrug-na\u00efve patients and in a sample of healthy subjects.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results :<\/jats:title>\n<jats:p> We compared NT1 (n=6), NT2 (n=6), and healthy controls (n=6). We found significantly\nreduced AEA levels in NT1 patients compared to both NT2 and controls. No differences were found\nbetween AEA levels in NT2 versus controls and between 2-AG levels in all groups, although a trend\ntoward a decrease in NT1 was evident. Finally, the CSF AEA level was related to CSF orexin levels in\nall subjects.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion :<\/jats:title>\n<jats:p>We demonstrated that the EC system is dysregulated in NT1.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871527319666200309115602","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T12:48:01Z","timestamp":1583758081000},"page":"142-147","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CSF Levels of the Endocannabinoid Anandamide are Reduced in Patients with Untreated Narcolepsy Type 1: A Pilot Study"],"prefix":"10.2174","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4505-2600","authenticated-orcid":true,"given":"Andrea","family":"Romigi","sequence":"first","affiliation":[{"name":"IRCCS Neuromed Sleep Medicine Center, Via Atinense, 18 Pozzilli (IS), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Bari","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome \u2018Tor Vergata', Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Liguori","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata', Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Izzi","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata', Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Rapino","sequence":"additional","affiliation":[{"name":"Faculty of Bioscience and Technology for Food, University of Teramo, Agriculture and Environment, Teramo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzia","family":"Nuccetelli","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome \u2018Tor Vergata', Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Battista","sequence":"additional","affiliation":[{"name":"Faculty of Bioscience and Technology for Food, University of Teramo, Agriculture and Environment, Teramo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Bernardini","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome \u2018Tor Vergata', Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Centonze","sequence":"additional","affiliation":[{"name":"IRCCS Neuromed Sleep Medicine Center, Via Atinense, 18 Pozzilli (IS), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola Biagio","family":"Mercuri","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata', Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Placidi","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u2018Tor Vergata', Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Maccarrone","sequence":"additional","affiliation":[{"name":"Campus Bio-Medico University of Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMra1500587","volume":"373","author":"Scammell T.E.","year":"2015","unstructured":"Scammell T.E.; Narcolepsy. N Engl J Med 2015,373(27),2654-2662","journal-title":"N Engl J Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.2174\/1871527317666180314115623","volume":"17","author":"Arias-Carrion O.","year":"2018","unstructured":"Arias-Carrion O.; Ortega-Robles E.; de Celis-Alonso B.; Palasz A.; Mendez-Rojas M.A.; Salas-Pacheco J.; Murillo-Rodriguez E.; Depletion of hypocretin\/orexin neurons increases cell proliferation in the adult subventricular zone. CNS Neurol Disord Drug Targets 2018,17(2),106-112","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pneurobio.2017.10.007","volume":"160","author":"Chiurchi\u00f9 V.","year":"2018","unstructured":"Chiurchi\u00f9 V.; van der Stelt M.; Centonze D.; Maccarrone M.; The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases. Prog Neurobiol 2018,160,82-100","journal-title":"Prog Neurobiol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nrd2553","volume":"7","author":"Di Marzo V.","year":"2008","unstructured":"Di Marzo V.; Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008,7(5),438-455","journal-title":"Nat Rev Drug Discov"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S1474-4422(19)30032-8","volume":"18","author":"Friedman D.","year":"2019","unstructured":"Friedman D.; French J.A.; Maccarrone M.; Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders. Lancet Neurol 2019,18,504-512","journal-title":"Lancet Neurol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.neubiorev.2016.10.005","volume":"71","author":"Prosp\u00e9ro-Garc\u00eda O.","year":"2016","unstructured":"Prosp\u00e9ro-Garc\u00eda O.; Amancio-Belmont O.; Becerril Mel\u00e9ndez A.L.; Ruiz-Contreras A.E.; M\u00e9ndez-D\u00edaz M.; Endocannabinoids and sleep. Neurosci Biobehav Rev 2016,71,671-679","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2174\/1871527318666190617162041","volume":"18","author":"Lunardelli M.L.","year":"2019","unstructured":"Lunardelli M.L.; Crupi R.; Siracusa R.; Cocuzza G.; Cordaro M.; Martini E.; Impellizzeri D.; Di Paola R.; Cuzzocrea S.; Co-ultraPEALut: role in preclinical and clinical delirium manifestations. CNS Neurol Disord Drug Targets 2019,18(7),530-554","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2174\/1871527318666190131121827","volume":"18","author":"Onesti E.","year":"2019","unstructured":"Onesti E.; Frasca V.; Ceccanti M.; Tartaglia G.; Gori M.C.; Cambieri C.; Libonati L.; Palma E.; Inghilleri M.; Short-term ultramicronized palmitoylethanolamide therapy in patients with myasthenia gravis: a pilot study to possible future implications of treatment. CNS Neurol Disord Drug Targets 2019,18(3),232-238","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.nbd.2018.08.012","volume":"120","author":"Naganuma F.","year":"2018","unstructured":"Naganuma F.; Bandaru S.S.; Absi G.; Mahoney C.E.; Scammell T.E.; Vetrivelan R.; Melanin-concentrating hormone neurons contribute to dysregulation of rapid eye movement sleep in narcolepsy. Neurobiol Dis 2018,120,12-20","journal-title":"Neurobiol Dis"},{"key":"ref=10","author":"Murillo-Rodr\u00edguez E.","year":"2019","unstructured":"Murillo-Rodr\u00edguez E.; Mill\u00e1n-Aldaco D.; Palomero-Rivero M.; Morales-Lara D.; Mechoulam R.; Drucker-Col\u00edn R.; Cannabidiol partially blocks the sleepiness in hypocretin-deficient rats. Preliminary data. CNS Neurol Disord Drug Targets 2019","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11325-015-1305-9","volume":"20","author":"Liguori C.","year":"2016","unstructured":"Liguori C.; Placidi F.; Izzi F.; Nuccetelli M.; Bernardini S.; Sarpa M.G.; Cum F.; Marciani M.G.; Mercuri N.B.; Romigi A.; Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time. Sleep Breath 2016,20(1),277-283","journal-title":"Sleep Breath"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.sleep.2014.07.002","volume":"15","author":"Liguori C.","year":"2014","unstructured":"Liguori C.; Placidi F.; Izzi F.; Albanese M.; Nuccetelli M.; Bernardini S.; Marciani M.G.; Mercuri N.B.; Romigi A.; May CSF beta-amyloid and tau proteins levels be influenced by long treatment duration and stable medication in narcolepsy? Sleep Med 2014,15(11),1424","journal-title":"Sleep Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/jsr.12130","volume":"23","author":"Liguori C.","year":"2014","unstructured":"Liguori C.; Placidi F.; Albanese M.; Nuccetelli M.; Izzi F.; Marciani M.G.; Mercuri N.B.; Bernardini S.; Romigi A.; CSF beta-amyloid levels are altered in narcolepsy: a link with the inflammatory hypothesis? J Sleep Res 2014,23(4),420-424","journal-title":"J Sleep Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1528-1167.2009.02334.x","volume":"51","author":"Romigi A.","year":"2010","unstructured":"Romigi A.; Bari M.; Placidi F.; Marciani M.G.; Malaponti M.; Torelli F.; Izzi F.; Prosperetti C.; Zannino S.; Corte F.; Chiaramonte C.; Maccarrone M.; Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy. Epilepsia 2010,51(5),768-772","journal-title":"Epilepsia"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/pcn.12780","volume":"72","author":"Ono T.","year":"2018","unstructured":"Ono T.; Kanbayashi T.; Yoshizawa K.; Nishino S.; Shimizu T.; Measurement of cerebrospinal fluid orexin-A (hypocretin-1) by enzyme-linked immunosorbent assay: A comparison with radioimmunoassay. Psychiatry Clin Neurosci 2018,72(11),849-850","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/pcn.12816","volume":"73","author":"Liguori C.","year":"2019","unstructured":"Liguori C.; Moresco M.; Izzi F.; Mercuri N.B.; Plazzi G.; Placidi F.; New revolution in the assessment of cerebrospinal fluid orexin-A: Enzyme-linked immunosorbent assay! Psychiatry Clin Neurosci 2019,73(4),194-195","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1001\/jamaneurol.2014.2510","volume":"71","author":"Liguori C.","year":"2014","unstructured":"Liguori C.; Romigi A.; Nuccetelli M.; Zannino S.; Sancesario G.; Martorana A.; Albanese M.; Mercuri N.B.; Izzi F.; Bernardini S.; Nitti A.; Sancesario G.M.; Sica F.; Marciani M.G.; Placidi F.; Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol 2014,71(12),1498-1505","journal-title":"JAMA Neurol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/978-3-319-75765-0_6","author":"Murillo-Rodr\u00edguez E.","year":"2018","unstructured":"Murillo-Rodr\u00edguez E.; Morales-Lara D.; Pastrana-Trejo J.C.; Mac\u00edas-Triana L.; Romero-Cordero K.; de-la-Cruz M.;  Cannabinoids, sleep, and the MCH system Melanin-Concentrating Hormone and Sleep 2018,121-130","journal-title":"Cannabinoids, sleep, and the MCH system Melanin-Concentrating Hormone and Sleep"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pbb.2013.04.006","volume":"108","author":"P\u00e9rez-Morales M.","year":"2013","unstructured":"P\u00e9rez-Morales M.; De La Herr\u00e1n-Arita A.K.; M\u00e9ndez-D\u00edaz M.; Ruiz-Contreras A.E.; Drucker-Col\u00edn R.; Prosp\u00e9ro-Garc\u00eda O.; 2-AG into the lateral hypothalamus increases REM sleep and cFos expression in melanin concentrating hormone neurons in rats. Pharmacol Biochem Behav 2013,108,1-7","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.conb.2017.04.008","volume":"44","author":"Ferreira J.G.P.","year":"2017","unstructured":"Ferreira J.G.P.; Bittencourt J.C.; Adamantidis A.; Melanin-concentrating hormone and sleep. Curr Opin Neurobiol 2017,44,152-158","journal-title":"Curr Opin Neurobiol"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.3390\/ph10040079","volume":"10","author":"Thompson M.D.","year":"2017","unstructured":"Thompson M.D.; Sakurai T.; Rainero I.; Maj M.C.; Kukkonen J.P.; Orexin receptor multimerization versus functional interactions: neuropharmacological implications for opioid and cannabinoid signalling and pharmacogenetics. Pharmaceuticals (Basel) 2017,10(4)","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2174\/1871527316666170223161908","volume":"16","author":"Murillo-Rodriguez E.","year":"2017","unstructured":"Murillo-Rodriguez E.; Pastrana-Trejo J.C.; Salas-Cris\u00f3stomo M.; de-la-Cruz M.; The endocannabinoid system modulating levels of consciousness, emotions and likely dream contents. CNS Neurol Disord Drug Targets 2017,16(4),370-379","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","volume":"30","author":"Izzo A.A.","year":"2009","unstructured":"Izzo A.A.; Borrelli F.; Capasso R.; Di Marzo V.; Mechoulam R.; Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009,30(10),515-527","journal-title":"Trends Pharmacol Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"Laprairie R.B.","year":"2015","unstructured":"Laprairie R.B.; Bagher A.M.; Kelly M.E.M.; Denovan-Wright E.M.; Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 2015,172(20),4790-4805","journal-title":"Br J Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","volume":"150","author":"Thomas A.","year":"2007","unstructured":"Thomas A.; Baillie G.L.; Phillips A.M.; Razdan R.K.; Ross R.A.; Pertwee R.G.; Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007,150(5),613-623","journal-title":"Br J Pharmacol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/bph.14440","volume":"176","author":"Tham M.","year":"2019","unstructured":"Tham M.; Yilmaz O.; Alaverdashvili M.; Kelly M.E.M.; Denovan-Wright E.M.; Laprairie R.B.; Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol 2019,176(10),1455-1469","journal-title":"Br J Pharmacol"},{"key":"ref=27","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24142583","volume":"24","author":"Calpe-L\u00f3pez C.","year":"2019","unstructured":"Calpe-L\u00f3pez C.; Garc\u00eda-Pardo M.P.; Aguilar M.A.; Cannabidiol treatment might promote resilience to cocaine and methamphetamine use disorders: A review of possible mechanisms. Molecules 2019,24(14)","journal-title":"Molecules"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-neuro-070815-014038","volume":"39","author":"Zlebnik N.E.","year":"2016","unstructured":"Zlebnik N.E.; Cheer J.F.; Beyond the CB1 receptor: is cannabidiol the answer for disorders of motivation? Annu Rev Neurosci 2016,39,1-17","journal-title":"Annu Rev Neurosci"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.15","volume":"2","author":"Leweke F.M.","year":"2012","unstructured":"Leweke F.M.; Piomelli D.; Pahlisch F.; Muhl D.; Gerth C.W.; Hoyer C.; Klosterk\u00f6tter J.; Hellmich M.; Koethe D.; Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012,2","journal-title":"Transl Psychiatry"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1017\/S1461145712001502","volume":"16","author":"Campos A.C.","year":"2013","unstructured":"Campos A.C.; Ortega Z.; Palazuelos J.; Foga\u00e7a M.V.; Aguiar D.C.; D\u00edaz-Alonso J.; Ortega-Guti\u00e9rrez S.; V\u00e1zquez-Villa H.; Moreira F.A.; Guzm\u00e1n M.; Galve-Roperh I.; Guimar\u00e3es F.S.; The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int J Neuropsychopharmacol 2013,16(6),1407-1419","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.pharmthera.2017.02.041","volume":"175","author":"Pisanti S.","year":"2017","unstructured":"Pisanti S.; Malfitano A.M.; Ciaglia E.; Lamberti A.; Ranieri R.; Cuomo G.; Abate M.; Faggiana G.; Proto M.C.; Fiore D.; Laezza C.; Bifulco M.; Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther 2017,175,133-150","journal-title":"Pharmacol Ther"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2174\/1871527316666170413101839","volume":"16","author":"Martinotti G.","year":"2017","unstructured":"Martinotti G.; Santacroce R.; Papanti D.; Elgharably Y.; Prilutskaya M.; Corazza O.; Synthetic cannabinoids: psychopharmacology, clinical aspects, psychotic onset. CNS Neurol Disord Drug Targets 2017,16(5),567-575","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"524","DOI":"10.2174\/187152731605170810115956","volume":"16","author":"Pichini S.","year":"2017","unstructured":"Pichini S.; Busardo F.P.; Editorial: cannabis: neurological correlates in abuse and medical use. CNS Neurol Disord Drug Targets 2017,16(5),524-526","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2174\/1871527316666170413105421","volume":"16","author":"Solimini R.","year":"2017","unstructured":"Solimini R.; Rotolo M.C.; Pichini S.; Pacifici R.; Neurological disorders in medical use of cannabis: an update. CNS Neurol Disord Drug Targets 2017,16(5),527-533","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/1871527318666181227123924","volume":"18","author":"Medeiros M.R.B.","year":"2019","unstructured":"Medeiros M.R.B.; de Mello Alves Rodrigues A.C.; Alves M.R.; Silva R.C.F.E.; Fel\u00edcio L.F.F.; Carneiro L.S.F.; Fagundes D.F.; Machado S.; Monteiro-Junior R.S.; Bibliometrics of CNS","journal-title":"CNS Neurol Disord Drug Targets"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/180033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T11:32:16Z","timestamp":1597404736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/180033\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527319666200309115602","relation":{},"ISSN":["1871-5273"],"issn-type":[{"type":"print","value":"1871-5273"}],"subject":[],"published":{"date-parts":[[2020,6,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}